2023 Q2 Form 10-Q Financial Statement
#000164033423000968 Filed on May 26, 2023
Income Statement
Concept | 2023 Q2 | 2023 Q1 | 2022 Q1 |
---|
Balance Sheet
Concept | 2023 Q2 | 2023 Q1 | 2022 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $0.00 | $0.00 | |
YoY Change | |||
Cash & Equivalents | $0.00 | $0.00 | |
Short-Term Investments | |||
Other Short-Term Assets | $500.00 | ||
YoY Change | |||
Inventory | |||
Prepaid Expenses | $500.00 | ||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $500.00 | $0.00 | |
YoY Change | |||
LONG-TERM ASSETS | |||
Property, Plant & Equipment | |||
YoY Change | |||
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | |||
YoY Change | |||
Total Long-Term Assets | $0.00 | $0.00 | |
YoY Change | |||
TOTAL ASSETS | |||
Total Short-Term Assets | $500.00 | $0.00 | |
Total Long-Term Assets | $0.00 | $0.00 | |
Total Assets | $500.00 | $0.00 | |
YoY Change | |||
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $19.60K | $10.00K | |
YoY Change | 96.0% | -0.1% | |
Accrued Expenses | |||
YoY Change | |||
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $90.52K | $60.03K | |
YoY Change | 50.79% | 95.18% | |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | |
YoY Change | |||
Other Long-Term Liabilities | |||
YoY Change | |||
Total Long-Term Liabilities | $0.00 | $0.00 | |
YoY Change | |||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $90.52K | $60.03K | |
Total Long-Term Liabilities | $0.00 | $0.00 | |
Total Liabilities | $90.52K | $60.03K | |
YoY Change | 50.79% | 95.18% | |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$379.1K | -$349.1K | |
YoY Change | 8.59% | 9.15% | |
Common Stock | $31.52K | ||
YoY Change | |||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | -$90.02K | -$60.03K | |
YoY Change | |||
Total Liabilities & Shareholders Equity | $500.00 | $0.00 | |
YoY Change |
Cashflow Statement
Concept | 2023 Q2 | 2023 Q1 | 2022 Q1 |
---|
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
19600 | usd |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
9800 | usd |
CY2023Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
90522 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-90022 | usd |
CY2023Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
500 | usd |
CY2023Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
750000000 | shares |
CY2023Q1 | us-gaap |
Cash
Cash
|
0 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1250 | usd |
CY2023Q1 | us-gaap |
Assets Current
AssetsCurrent
|
500 | usd |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
1250 | usd |
CY2023Q1 | us-gaap |
Assets
Assets
|
500 | usd |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
80722 | usd |
CY2023Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
31518 | usd |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
31518 | usd |
CY2022Q4 | us-gaap |
Assets
Assets
|
1250 | usd |
CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
257587 | usd |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-368577 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-79472 | usd |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1250 | usd |
CY2022Q1 | us-gaap |
Revenues
Revenues
|
0 | usd |
CY2022Q1 | us-gaap |
Professional Fees
ProfessionalFees
|
9725 | usd |
CY2022Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
0 | usd |
CY2022Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
9725 | usd |
CY2022Q1 | huaizhong |
Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
|
-0.0003 | |
CY2022Q1 | huaizhong |
Basic And Diluted Weighted Average Common Shares Outstanding
BasicAndDilutedWeightedAverageCommonSharesOutstanding
|
31518466 | shares |
CY2023Q1 | us-gaap |
Professional Fees
ProfessionalFees
|
9800 | usd |
CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
750 | usd |
CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
10550 | usd |
CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-10550 | usd |
CY2023Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001593204 | |
CY2023Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2023Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--10-31 | |
CY2023Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2023Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
750000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
31518466 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
31518466 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
31518466 | shares |
CY2023Q1 | dei |
Document Type
DocumentType
|
10-Q | |
CY2023Q1 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
CY2023Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-01-31 | |
CY2023Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2023Q1 | dei |
Entity File Number
EntityFileNumber
|
000-55369 | |
CY2023Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
HUAIZHONG HEALTH GROUP, INC. | |
CY2023Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
NV | |
CY2023Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
90-1020141 | |
CY2023Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
Tianan Technology Park | |
CY2023Q1 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
13/F Headquarters Center Building 16 | |
CY2023Q1 | dei |
Entity Address Address Line3
EntityAddressAddressLine3
|
555 Panyu North Ave, Panyu District | |
CY2023Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Guangzhou City | |
CY2023Q1 | dei |
Entity Address Country
EntityAddressCountry
|
CN | |
CY2023Q1 | dei |
City Area Code
CityAreaCode
|
86 (20) | |
CY2023Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
2982 9356 | |
CY2023Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2023Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2023Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2023Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2023Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | |
CY2023Q1 | dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
false | |
CY2023Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2023Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
31518466 | shares |
CY2022Q4 | us-gaap |
Cash
Cash
|
0 | usd |
CY2023Q1 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
500 | usd |
CY2023Q1 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
70922 | usd |
CY2022Q4 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
70922 | usd |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
80722 | usd |
CY2023Q1 | us-gaap |
Liabilities
Liabilities
|
90522 | usd |
CY2023Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
31518466 | shares |
CY2023Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
257587 | usd |
CY2023Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-379127 | usd |
CY2023Q1 | us-gaap |
Revenues
Revenues
|
0 | usd |
CY2022Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9725 | usd |
CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-10550 | usd |
CY2022Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-9725 | usd |
CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2022Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10550 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9725 | usd |
CY2023Q1 | huaizhong |
Net Loss Per Common Share Basic And Diluted
NetLossPerCommonShareBasicAndDiluted
|
-0.0003 | |
CY2023Q1 | huaizhong |
Basic And Diluted Weighted Average Common Shares Outstanding
BasicAndDilutedWeightedAverageCommonSharesOutstanding
|
31518466 | shares |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-79472 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10550 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-90022 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-50301 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9725 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-60026 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10550 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9725 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
0 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
0 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
750 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
0 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
9800 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
50 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
0 | usd |
CY2022Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-9675 | usd |
CY2023Q1 | huaizhong |
Proceeds From Related Party Advances Funding Operations
ProceedsFromRelatedPartyAdvancesFundingOperations
|
0 | usd |
CY2022Q1 | huaizhong |
Proceeds From Related Party Advances Funding Operations
ProceedsFromRelatedPartyAdvancesFundingOperations
|
9675 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | usd |
CY2022Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
9675 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
0 | usd |
CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
0 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
0 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
0 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
0 | usd |
CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
0 | usd |
CY2023Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
0 | usd |
CY2022Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
0 | usd |
CY2023Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
0 | usd |
CY2022Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
0 | usd |
CY2023Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p> | |
CY2023Q1 | huaizhong |
Reclassification Policy Textblock
ReclassificationPolicyTextblock
|
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain accounts from prior periods have been reclassified to conform to the current period presentation.</p> | |
CY2023Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-379127 | usd |